|
WINNIPEG, Manitoba – June 18, 2009 - Miraculins Inc. (TSX-V:MOM) (the “Company”), a company focused on developing and commercializing medical diagnostic tests for unmet clinical needs, has closed its previously announced private placement offering (the "Offering") with aggregate gross proceeds to the Company of $400,000 from the sale of 8,000,000 units ("Units") at a price of $0.05 per Unit. Each Unit is comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a "Warrant"). Each Warrant entitles the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued. The net proceeds of the Offering shall be used for research and development and working capital purposes. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws and the policies of the TSX Venture Exchange.
Read More
|
|
WINNIPEG, Manitoba – June 12, 2009 - Miraculins Inc. (TSX-V:MOM), a company focused on developing and commercializing medical and diagnostic tests for unmet clinical needs, is pleased to announce that it has increased the current private placement offering (the “Offering”), first reported on April 27, 2009, from a maximum of 5,000,000 units (“Units”) to 8,000,000 Units, for total gross proceeds of up to $400,000. As previously announced, each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued.
Read More
|
|
Miraculins Inc. (TSX-V:MOM), a Canadian medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs and Diagnostic Technologies Ltd. (DTL), an Israel based developer of diagnostic kits and devices for monitoring pregnancies at risk are pleased to announce they have been notified by the CIIRDF (Canada-Israel Industrial Research and Development Foundation) of the approval of $782,000 in grant funding, over a two year period, for a joint research and development project.
Read More
|
|
WINNIPEG, Manitoba – June 25th, 2009– Miraculins Inc. (TSX-V:MOM), a Canadian company focused on developing and commercializing medical diagnostic tests for unmet clinical needs, is pleased to announce the finalization of a Research Collaboration Agreement with Diagnostic Technologies Ltd. (DTL), an Israel based developer of diagnostic kits and devices for monitoring pregnancy disorders. In addition, Miraculins also announces the execution of a Cooperation and Project Funding Agreement with DTL and CIIRDF (Canada-Israel Industrial Research and Development Foundation).
Read More
|
|
WINNIPEG, Manitoba – August 28, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces that it has agreed to issue 94,412 of its common shares to Diagnos Inc. at a price of $0.05 per common share (net cash value of $4,720.60) as part of the compensation owing for services rendered in accordance with the terms of an agreement between the parties announced December 4, 2007.
Read More
|
|
|